Mobile Android Apps<br />
The Next Generation in Women’s Health Solutions<br />Advancing Women’s Breast Health<br />
Patented, FDA-Cleared <br />Breast Cancer Risk Assessment Test<br />Inexpensive, Cost Effective, Painless, Safe Adjunct to...
Atossa Genetics <br />Two-Pronged Medical Solution<br />Collect <br />NAF<br />Diagnose<br />NAF<br />Cytology & Biomarker...
Atossa Genetics <br />Two-Pronged Business Model<br />Product and Service Revenue <br />$13 Billion Annual US Market<br />...
The Breast Cancer Problem<br />1 In 8 Lifetime Cancer Risk<br />519,000 New Cases per Year<br />Literally One Death/Minute...
Breast Cancer <br />Doesn’t Happen Overnight<br />Takes > 8 Years to Develop <br />Identifying Pre-Cancerous Changes Empow...
Pap Test <br />for Breast Cancer<br />Both Cervical and Breast Cancer Develop Over About a Decade<br />The Cervix Undergoe...
Atossa <br />Products & Services<br />SERVICES: <br />Slides Prepared and Interpreted in Atossa Laboratory; Report Prepare...
Patient Flow and Procedures<br />Painless,<br />10 minute Test - <br />No radiation<br />MAMMOGRAPHY OR<br />CLINIC<br />P...
Atossa Services:Patented Cytology and IHC<br />Patient List Prices are Two-to Over Three-Times Medicare Reimbursement Rate...
Clinical Utility:Over 200 papers and 20,000 Women<br />NIPPLE ASPIRATE FLUID CYTOLOGY AND THE GAIL MODEL FOR BREAST CANCER...
Why Should a Women <br />Have a MASCT Test?<br />Predicts breast cancer up to 8 years in advance<br />Mammography cannot d...
How Do You Use the Information?<br />Step 1: Test NAF For Hyperplasia<br />  			Step 2: If Present, Treat For 6 Months<br ...
MASCT Procedures & Revenue<br />At $372 Per Patient, Total Available Market In<br />the U.S. Exceeds $13 Billion Per Year<...
All MASCT Steps Are Patented<br />US Patent 6,887,210<br />US Patent 6,889,073<br />Mammography Clinic or office<br />Pati...
Worldwide Patent Protection:14 Issued Patents with Additional Pending<br />Canada<br />Europe<br />Japan<br />United State...
Competition:Breast Cancer Screening<br />Neomatrix is a privately held company with a device that collects fluid From the ...
MASCT Launch Calendar<br />Q1 2011<br />MANUFACTURING FOR FIELD TESTING  DONE<br />LABORATORY IDENTIFIED AND LEASED DONE<b...
2nd Generation Product:Oxy-MASCT System<br />Additional NAF would be aid biomarker<br />    detection<br />Atossa discover...
2nd Generation Services:Molecular Biomarkers<br />MicroRNA Patterns<br />Next Gen Sequencing<br />DNA Methylation<br />Tra...
Management & Board of Directors<br />Steven C. Quay, M.D., Ph.D., Chairman, CEO<br />Christopher Benjamin, CFO <br />Shu-C...
5 FDA Approved Drugs and 1 Device Invented and Developed<br />Steven C. Quay, M.D., Ph.D.<br />23<br />
Pharmaceutical Business Experience:Patent, Development, Marketing<br />Over $1.3 Billion In Negotiated Milestone <br />Pay...
Princess Atossa<br />“IN 518 B.C., PRINCESS ATOSSA, WIFE OF DARIUS THE GREAT, BECAME THE FIRST WOMAN IN RECORDED HISTORY T...
The Next Generation in Women’s Health Solutions<br />Advancing Women’s Breast Health<br />Steven C. Quay, MD, PhDChairman,...
Upcoming SlideShare
Loading in...5
×

Atossa Personalized Medicine Slides

806
-1

Published on

January 18-19, 2011 presentation

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
806
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • $322 per Patient Weighted AverageCosts are under $20 per slide
  • Breast cancer prevention
  • As MASCT System biomarker tests expand the availability of additional NAF would be usefulAdministration of oxytocin 5 to 10 minutes before MASCT collection provides up to a 10-fold increase in NAFUS Patent 5,798,226, exclusively licensed to Atossa, covers the use of oxytocin for NAF collectionAdditional clinical trials and FDA approval will be required for Oxy-MASCT commercialization
  • Atossa Personalized Medicine Slides

    1. 1. Mobile Android Apps<br />
    2. 2. The Next Generation in Women’s Health Solutions<br />Advancing Women’s Breast Health<br />
    3. 3. Patented, FDA-Cleared <br />Breast Cancer Risk Assessment Test<br />Inexpensive, Cost Effective, Painless, Safe Adjunct to Mammography<br />Potential to Significantly Reduce Breast Cancer <br />“The Pap Test for Breast Cancer”<br />3<br />
    4. 4. Atossa Genetics <br />Two-Pronged Medical Solution<br />Collect <br />NAF<br />Diagnose<br />NAF<br />Cytology & Biomarker <br />Services<br />MASCT System Product<br />4<br />
    5. 5. Atossa Genetics <br />Two-Pronged Business Model<br />Product and Service Revenue <br />$13 Billion Annual US Market<br />Near-Term Launch in 2011<br />Experienced Management<br />5<br />
    6. 6. The Breast Cancer Problem<br />1 In 8 Lifetime Cancer Risk<br />519,000 New Cases per Year<br />Literally One Death/Minute<br />$3.8 Billion Financial Burden<br />6<br />
    7. 7. Breast Cancer <br />Doesn’t Happen Overnight<br />Takes > 8 Years to Develop <br />Identifying Pre-Cancerous Changes Empowers Patients & Physicians<br />Obtaining Samples Has Not Been Practical- Until Now<br />Despite Shortcomings, 38.9 MM Women in U.S. Have Annual Mammograms<br />7<br />
    8. 8. Pap Test <br />for Breast Cancer<br />Both Cervical and Breast Cancer Develop Over About a Decade<br />The Cervix Undergoes Similar Pre-Cancerous Changes<br />PAP Test has lowered Cervical Cancer by 74%<br />PAP Test is Most Successful Screening Test in Medical History<br />8<br />
    9. 9. Atossa <br />Products & Services<br />SERVICES: <br />Slides Prepared and Interpreted in Atossa Laboratory; Report Prepared: Medicare: $322 per Patient<br />PRODUCTS: <br />Mammary Aspirate Specimen Cytology Test or (MASCT)<br />Reusable device for collecting Nipple Aspirate Fluid (NAF), which contains cells<br />Pump: $200<br />Patient kit: $50<br />9<br />
    10. 10. Patient Flow and Procedures<br />Painless,<br />10 minute Test - <br />No radiation<br />MAMMOGRAPHY OR<br />CLINIC<br />PATIENT WAITING<br />FOR TEST<br />Cytology report <br />START<br />MASCT SYSTEM<br />COLLECTS SAMPLE<br />ATOSSA LABORATORY<br />PREPARES SLIDES<br />SAMPLES ARE SHIPPED<br />FOR ANALYSIS<br />10<br />
    11. 11. Atossa Services:Patented Cytology and IHC<br />Patient List Prices are Two-to Over Three-Times Medicare Reimbursement Rates<br />80% Normal<br />INITIAL ROUTINE STAINING<br />20% Hyperplasia<br />Reflex IHC<br />11<br />
    12. 12. Clinical Utility:Over 200 papers and 20,000 Women<br />NIPPLE ASPIRATE FLUID CYTOLOGY AND THE GAIL MODEL FOR BREAST CANCER RISK ASSESSMENT IN A SCREENING POPULATION<br /> Jeffrey A. Tice,1 Rei Miike,2 Kelly Adduci,3 Nicholas L. Petrakis,2 Eileen King,2 and Margaret R. Wrensch2<br /> 1 Division of General Internal Medicine, Department of Medicine, 2Department of Epidemiology and Biostatistics, and<br /> 3 Cancer Center, University of California, San Francisco, San Francisco, California<br /> BREAST CANCER RISK IN WOMEN WITH ABNORMAL CYTOLOGY IN NIPPLE ASPIRATES OF BREAST FLUID<br /> M. R. Wrensch, N. L. Petrakis,R. Miike, E. B. King, J. Neuhaus, M. M. Lee (Department of Epidemiology and Biostatistics, School of Medicine), K. Chew (Cancer Center), University of California, San Francisco; M. Rhys, School of Nursing, University of California, Los Angeles<br /> THE ROLE OF NIPPLE-ASPIRATE FLUID CYTOLOGY IN BREAST-CANCER RISK SCREENING<br /> Joel Bentz, M.D., Clinical Professor of Pathology, University of Utah, Salt Lake City, UT<br />12<br />
    13. 13. Why Should a Women <br />Have a MASCT Test?<br />Predicts breast cancer up to 8 years in advance<br />Mammography cannot detect pre-cancers<br />Actionable information<br />Increased screening frequency<br />Preventive measures<br />MASCT is simple, quick, <br />convenient, painless, safe <br />(no radiation), and cost effective<br />13<br />
    14. 14. How Do You Use the Information?<br />Step 1: Test NAF For Hyperplasia<br /> Step 2: If Present, Treat For 6 Months<br /> Step 3: Retest NAF For Treatment Success<br />No Mammography <br />Changes<br />33 patients 6 mo therapy<br />BASELINE:<br />CYTOLOGY, ADH<br />PSA BIOMARKER = 37.5<br />FOLLOW-UP:<br />CYTOLOGY, IMPROVED<br />PSA BIOMARKER = 112<br />Sauter et al. Breast. 16(5):489-94, 2007<br />14<br />
    15. 15. MASCT Procedures & Revenue<br />At $372 Per Patient, Total Available Market In<br />the U.S. Exceeds $13 Billion Per Year<br />MAMMOGRAPHY<br />CLINIC<br />Mammography Clinic Demographics<br />8600 Centers in the U.S.<br />Each Center Provides 4500 Mammograms per Year<br />38.9 Million Mammograms per Year in the U.S.<br />15<br />
    16. 16. All MASCT Steps Are Patented<br />US Patent 6,887,210<br />US Patent 6,889,073<br />Mammography Clinic or office<br />Patient waiting for test<br />Cytology report <br />US Patent 6,887,210<br />US Patent 6,889,073<br />US Patent 6,889,073<br />MASCT System<br />Collects NAF<br />ATOSSA LABORATORY PREPARES SLIDES<br />SAMPLES SHIPPED FOR ANALYSIS<br />16<br />
    17. 17. Worldwide Patent Protection:14 Issued Patents with Additional Pending<br />Canada<br />Europe<br />Japan<br />United States<br />HONG KONG<br />Australia<br />17<br />
    18. 18. Competition:Breast Cancer Screening<br />Neomatrix is a privately held company with a device that collects fluid From the breast for screening<br /> 250 machines placed<br /> Performed over 50,000 tests<br />18<br />
    19. 19. MASCT Launch Calendar<br />Q1 2011<br />MANUFACTURING FOR FIELD TESTING DONE<br />LABORATORY IDENTIFIED AND LEASED DONE<br />Q2 2011<br />FIELD TESTING BEGINS<br />LABORATORY CLIA-REGISTRATION<br />Q3 2011<br />REGIONAL ROLL-OUT IN PACIFIC <br />NORTHWEST<br />Q3 2012 <br /> NATIONAL ROLL-OUT<br />19<br />
    20. 20. 2nd Generation Product:Oxy-MASCT System<br />Additional NAF would be aid biomarker<br /> detection<br />Atossa discovered oxytocin increases NAF 10X<br />US Patent 5,798,226 covers oxytocin use for<br /> NAF collection<br />Additional clinical trials & FDA approval needed<br />20<br />
    21. 21. 2nd Generation Services:Molecular Biomarkers<br />MicroRNA Patterns<br />Next Gen Sequencing<br />DNA Methylation<br />Transcriptome<br />Proteomics<br />Glycosylation<br />
    22. 22. Management & Board of Directors<br />Steven C. Quay, M.D., Ph.D., Chairman, CEO<br />Christopher Benjamin, CFO <br />Shu-Chih Chen, Ph.D., Chief Scientific Officer<br />Mr. John Barnhart, Former Senior Walt Disney Executive<br />Stephen Galli, M.D., Chairman, Pathology Dept., <br /> Stanford Medical School<br />Alexander Cross, Ph.D., Former CEO, Syntex Corporation<br />22<br />
    23. 23. 5 FDA Approved Drugs and 1 Device Invented and Developed<br />Steven C. Quay, M.D., Ph.D.<br />23<br />
    24. 24. Pharmaceutical Business Experience:Patent, Development, Marketing<br />Over $1.3 Billion In Negotiated Milestone <br />Payments, Up-front Payments, And Other Consideration<br />24<br />
    25. 25. Princess Atossa<br />“IN 518 B.C., PRINCESS ATOSSA, WIFE OF DARIUS THE GREAT, BECAME THE FIRST WOMAN IN RECORDED HISTORY TO BE DIAGNOSED WITH BREAST CANCER. SHE WAS TREATED BY THE COURT PHYSICIAN, DEMOCEDES, BUT DIED SHORTLY THEREAFTER. <br />“ATOSSA GENETICS IS DEDICATED TO HER AND THE MILLIONS OF WOMEN WHO HAVE SUFFERED FROM THIS DREADED DISEASE.”<br />Steven C. Quay, M.D., Ph.D.<br />Founder, Chairman, President and CEO<br />Princess Atossa<br />25<br />
    26. 26. The Next Generation in Women’s Health Solutions<br />Advancing Women’s Breast Health<br />Steven C. Quay, MD, PhDChairman, CEO, And President<br />4105 E Madison St, Suite 320 Seattle, WA 98112<br />T: 206.325.6086 STEVEN.QUAY@ATOSSAGENETICS.COM<br />26<br />

    ×